MRK – Merck & Co., Inc.
MRK — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
1.18
Margin Of Safety %
-17
Put/Call OI Ratio
0.7
EPS Next Q Diff
0.75
EPS Last/This Y
-2.17
EPS This/Next Y
4.64
Price
121.01
Target Price
129.5
Analyst Recom
1.77
Performance Q
14.83
Upside
110.8%
Beta
0.3
Ticker: MRK
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-04 | MRK | 120.26 | 0.67 | 1.59 | 578366 |
| 2026-03-05 | MRK | 116.03 | 0.67 | 0.73 | 592601 |
| 2026-03-09 | MRK | 116.93 | 0.68 | 0.76 | 591199 |
| 2026-03-10 | MRK | 117.09 | 0.69 | 0.38 | 591840 |
| 2026-03-11 | MRK | 116.4 | 0.69 | 0.21 | 594710 |
| 2026-03-12 | MRK | 115.91 | 0.69 | 0.28 | 598931 |
| 2026-03-17 | MRK | 115.85 | 0.82 | 0.87 | 536310 |
| 2026-03-18 | MRK | 114.5 | 0.81 | 1.65 | 539652 |
| 2026-03-19 | MRK | 114.2 | 0.82 | 0.67 | 544691 |
| 2026-03-20 | MRK | 114.18 | 0.80 | 0.85 | 555582 |
| 2026-03-23 | MRK | 115.67 | 0.74 | 0.88 | 469664 |
| 2026-03-24 | MRK | 116.38 | 0.73 | 0.34 | 483251 |
| 2026-03-25 | MRK | 119.38 | 0.69 | 0.30 | 499175 |
| 2026-03-26 | MRK | 118.93 | 0.67 | 0.82 | 514201 |
| 2026-03-27 | MRK | 120 | 0.68 | 0.36 | 518577 |
| 2026-03-30 | MRK | 118.15 | 0.70 | 0.54 | 505647 |
| 2026-03-31 | MRK | 120.31 | 0.70 | 1.35 | 511447 |
| 2026-04-01 | MRK | 120.81 | 0.71 | 1.63 | 516037 |
| 2026-04-02 | MRK | 121 | 0.70 | 1.24 | 518594 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-04 | MRK | 120.29 | -159.1 | -4254.9 | 5.11 |
| 2026-03-05 | MRK | 116.04 | -159.0 | -4888.5 | 5.12 |
| 2026-03-06 | MRK | 115.78 | -159.0 | -4353.3 | 5.12 |
| 2026-03-09 | MRK | 117.12 | -159.0 | -3926.5 | 5.12 |
| 2026-03-10 | MRK | 117.09 | -159.0 | -4116.8 | 5.12 |
| 2026-03-11 | MRK | 116.21 | -159.0 | -4449.1 | 5.12 |
| 2026-03-12 | MRK | 115.93 | -159.0 | -4365.2 | 5.12 |
| 2026-03-13 | MRK | 115.61 | -159.0 | -4368.8 | 5.12 |
| 2026-03-17 | MRK | 115.88 | -159.0 | -4144.9 | 5.12 |
| 2026-03-18 | MRK | 114.46 | -159.0 | -4405.4 | 5.12 |
| 2026-03-19 | MRK | 114.22 | -159.0 | -5436.6 | 5.12 |
| 2026-03-20 | MRK | 114.18 | -159.0 | -5402.1 | 5.12 |
| 2026-03-23 | MRK | 115.75 | -159.0 | -5190.9 | 5.12 |
| 2026-03-24 | MRK | 116.37 | -159.5 | -5308.7 | 5.13 |
| 2026-03-25 | MRK | 119.38 | -159.0 | -5006.1 | 5.13 |
| 2026-03-26 | MRK | 118.96 | -159.0 | -5445.6 | 5.13 |
| 2026-03-27 | MRK | 119.62 | -159.0 | -5418.2 | 5.13 |
| 2026-03-30 | MRK | 118.11 | -159.0 | -5697.7 | 5.13 |
| 2026-03-31 | MRK | 120.31 | -159.0 | -5223.1 | 5.13 |
| 2026-04-01 | MRK | 120.83 | -159.0 | -5438.0 | 5.13 |
| 2026-04-02 | MRK | 121.01 | -159.0 | -5484.8 | 5.13 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-04 | MRK | -13.80 | 0.76 | 1.14 |
| 2026-03-05 | MRK | -13.80 | 0.76 | 1.14 |
| 2026-03-06 | MRK | -13.80 | 0.76 | 1.14 |
| 2026-03-09 | MRK | -13.80 | 0.52 | 1.14 |
| 2026-03-10 | MRK | -13.80 | 0.52 | 1.14 |
| 2026-03-11 | MRK | -13.80 | 0.52 | 1.26 |
| 2026-03-12 | MRK | -13.80 | 0.52 | 1.26 |
| 2026-03-13 | MRK | -13.80 | 0.52 | 1.26 |
| 2026-03-17 | MRK | -13.80 | 0.61 | 1.26 |
| 2026-03-18 | MRK | -13.79 | 0.61 | 1.26 |
| 2026-03-19 | MRK | -13.80 | 0.61 | 1.26 |
| 2026-03-20 | MRK | -13.80 | 0.61 | 1.26 |
| 2026-03-23 | MRK | -13.79 | 0.53 | 1.26 |
| 2026-03-24 | MRK | -13.79 | 0.53 | 1.26 |
| 2026-03-25 | MRK | -13.80 | 0.53 | 1.18 |
| 2026-03-26 | MRK | -13.80 | 0.53 | 1.18 |
| 2026-03-27 | MRK | -13.80 | 0.53 | 1.18 |
| 2026-03-30 | MRK | -13.80 | 0.53 | 1.18 |
| 2026-03-31 | MRK | -13.80 | 0.53 | 1.18 |
| 2026-04-01 | MRK | -13.80 | 0.53 | 1.18 |
| 2026-04-02 | MRK | -13.80 | 0.53 | 1.18 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.19
Avg. EPS Est. Current Quarter
-1.31
Avg. EPS Est. Next Quarter
1.94
Insider Transactions
-13.8
Institutional Transactions
0.53
Beta
0.3
Average Sales Estimate Current Quarter
15877
Average Sales Estimate Next Quarter
16390
Fair Value
100
Quality Score
96
Growth Score
77
Sentiment Score
80
Actual DrawDown %
10.1
Max Drawdown 5-Year %
-43.4
Target Price
129.5
P/E
16.61
Forward P/E
12.48
PEG
2.01
P/S
4.6
P/B
5.69
P/Free Cash Flow
24.18
EPS
7.28
Average EPS Est. Cur. Y
5.13
EPS Next Y. (Est.)
9.76
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
28.12
Relative Volume
0.53
Return on Equity vs Sector %
7.1
Return on Equity vs Industry %
-2.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
-5484.8
◆
MRK
Healthcare
$120.87
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
60.8
Range 1M
78.8%
Sup Dist
0.7%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-43%
EPS NY
89.3%
52W%
90.4%
Long-Term Value
Quality companies, undervalued
WATCH
🟢 BUY
+87.5% upside
Upside
+87.5%
Quality
96
MoS
-17%
Merck & Company, Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 73000
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
MRK
Latest News
—
Caricamento notizie per MRK…
stock quote shares MRK – Merck & Co., Inc. Stock Price stock today
news today MRK – Merck & Co., Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MRK – Merck & Co., Inc. yahoo finance google finance
stock history MRK – Merck & Co., Inc. invest stock market
stock prices MRK premarket after hours
ticker MRK fair value insiders trading